AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00778050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 600mg
Study NCT04740853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy+Special Education
Description: Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
Study NCT04740853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensory Integration Therapy+Special Education
Description: Sensory integration is a theory first put forward by Ayres in 1972. It is a neurological process that organizes sensory stimuli from our body and our environment for use in the daily life. When the sensory integrity organization of individuals is provided, it is possible to use their body effectively against the environment. Sensory integration therapy, which is defined as a physiologically based process by Ayres and Dunn, also provides changes in individuals' occupations.
Study NCT02178514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula fed with BabyNes Nutrition System
Study NCT01064544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light therapy with the device: EnergyLight
Description: 2 hr of light therapy during each hemodialysis session
Study NCT03766035 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass DS I - II
Description: The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
Study NCT00190268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Description: 3,4-diaminopyridine
Study NCT03248037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil
Description: netarsudil opthalmic solution 0.02%
Study NCT03248037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study NCT04384900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Description: Patients are placed in a prone position using specialized equipment.
Study NCT04384900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone position ventilation
Description: Patients are placed in a prone position using specialized equipment.
Study NCT02650817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD1901
Description: RAD1901, a novel selective ER degrader (SERD)
Study NCT03613298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU (Focal One®)
Description: Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
Study NCT02870491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Distribution
Description: Caretakers of children under 5-years-old will have access to free ORS and zinc
Study NCT02870491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preemptive Delivery
Description: Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
Study NCT02788487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue retaining device
Description: Tongue retaining device is used for 3 weeks
Study NCT02788487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue retaining device
Description: Tongue retaining device is used for 3 weeks
Study NCT02788487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is used for 3 weeks
Study NCT02788487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is used for 3 weeks
Study NCT05496023 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: 1. Pre-PCI angio-FFR was calculated and virtual pullback was generated~2. Automated algorithm to calculate delta angio-FFR per unit length and co-registered onto coronary angiogram was developed~3. PCI was performed using 2nd generation DES
Study NCT03409744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Intravenous (IV) administration
Study NCT02460510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Study NCT02460510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% hypertonic saline
Study NCT03470077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nalbuphine 0.1 mg/kg with induction of anesthesia.
Description: Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~.
Study NCT03470077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nalbuphine 0.1 mg/kg at the end of surgery.
Description: Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382
Description: Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
Study NCT01482611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
Study NCT03248297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin tablet
Study NCT03248297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin and amoxicillin
Description: azithromycin and amoxicillin
Study NCT03248297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study NCT03248297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT02399332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community pharmacist involvement
Description: Collaborative involvement of the community pharmacists in formulating and following complex care plans
Study NCT03528421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19
Description: CAR-T cells
Study NCT03528421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Two days before cell infusion, all patients will be treated with fludarabine for 3 days
Study NCT03528421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Study NCT04614506 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
Study NCT04614506 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: These will be an ambulatory EEG recordings that span 24 hours and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
Study NCT02980016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rifapentine + isoniazid
Description: Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
Study NCT02980016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
Study NCT04078386 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received the test group Placebo weekly administered subcutaneously for 24 times.
Study NCT04143958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agalsidase beta (GZ419828)
Description: Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
Study NCT04143958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: agalsidase alfa
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
Study NCT04078386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240 mg
Description: Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
Study NCT04078386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg
Description: Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
Study NCT03351803 — intervention group
Intervention type: OTHER
Intervention: BFOR Digital Health solution/Web Portal
Description: A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
Study NCT00600522 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided hepatectomy
Description: After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~1. Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~2. Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~3. Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended.
Study NCT00501631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIVITROL 380 mg
Description: Administered via IM injection once every 4 weeks.
Study NCT00501631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VIVITROL 380 mg
Description: Administered via IM injection once every 4 weeks.
Study NCT01994200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary Team-Based Approach
Description: Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
Study NCT01994200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
Study NCT02837588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermy treatment with MJS electrode
Description: 30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
Study NCT00902863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YOGA
Description: Patients with chronic pain will undergo a six week course of YOGA
Study NCT03085303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body Blue Light Device
Description: Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
Study NCT03085303 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Full Body Blue Light Device
Description: Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
Study NCT03448848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCAA preparation Intravenous infusion
Description: BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
Study NCT03448848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline
Description: sterile normal saline in a volume equal to the study drug
Study NCT06436716 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: Every patient needs an MRI to assess spinal cord injury. This is one of the clinically necessary examinations.
Study NCT01082419 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination.
Study NCT01082419 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once.
Study NCT01082419 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ARFI measurement
Description: ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing.
Study NCT02742207 — intervention group
Intervention type: OTHER
Intervention: Electrical atrial fibrillation Cardioversion
Description: Electrical cardioversion for patients admitted for Atrial Fibrillation
Study NCT02742207 — intervention group
Intervention type: OTHER
Intervention: Cardioversion
Description: Electrical cardioversion for patients admitted for Atrial Fibrillation
Study NCT03314480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized physical examination
Description: Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
Study NCT01122173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Atrial fibrillation ablation procedure
Study NCT00856180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00856180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01426581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-To-Goal
Description: Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
Study NCT01426581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
Study NCT03387293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-LII Breakfast
Description: This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
Study NCT03387293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LGI-HII Breakfast
Description: In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
Study NCT03225430 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural treatment for tics
Description: Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
Study NCT03225430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive psychophysiological
Description: Focus on the processes influencing thoughts and behaviors underlying tics.
Study NCT03340883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: a solution for intravenous (IV) administration, diluted and administered Q2W
Study NCT03527264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab induction
Description: 2 doses Nivolumab 240mg IV
Study NCT03527264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
Study NCT03527264 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field
Study NCT03527264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab with chemoradiation
Description: Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
Study NCT03527264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance
Description: Nivolumab 480 mg IV every 4 weeks for 2 years
Study NCT00626639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) bolus injection
Study NCT00626639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Administered by intravenous (IV) bolus injection
Study NCT00626639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
Study NCT00626639 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation \[one fraction per day\])
Study NCT00626639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
Study NCT00626639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
Study NCT00644059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted trivalent inactivated subunit influenza vaccine
Description: Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.